Regenerative Medical Technology Group Inc.

Regenerative Medical Technology Group (RMTG), through its subsidiary Global Stem Cells Group (GSCG), operates as a vertically integrated organization in regenerative medicine. The company combines physician education and global influence through the International Society for Stem Cell Applications (ISSCA), advanced manufacturing and product innovation via Cellgenic, and a clinical network for patient care and data generation. This structure aims to drive demand, supply quality-controlled biologics and therapeutics, validate protocols through clinical applications, and use digital technologies for revenue and innovation. RMTG's mission is to enable physicians globally to deliver regenerative medicine benefits, including stem cell therapies, exosomes, peptides, and advanced combination protocols, to patients. In 2026, the company focused on four core pillars: ISSCA for physician acquisition and protocol standardization; Cellgenic for manufacturing and product portfolio; premium clinical centers for revenue and validation; and international market expansion for global scaling. The company supports physicians, medical providers, and affiliated clinics with protocols, biologics, automated processing systems, diagnostic tools, and training. Its revenue model includes professional training and certifications, recurring sales of Cellgenic products (exosomes, mesenchymal stem cells, peptides, and combination therapies), premium clinical treatments, equipment and kits, digital subscriptions, licensing, partnerships, and franchise arrangements. This integrated structure aims to create competitive advantages such as customer lifetime value, recurring revenue predictability, ecosystem lock-in, network effects, and proprietary clinical data assets.